Test Would Assess Risk Of Cardiovascular Disease Using Enzyme’s Presence
This article was originally published in The Gray Sheet
Executive Summary
diaDexus and GlaxoSmithKline are in the early stages of developing a joint diagnostic and therapeutic approach to treat patients by detecting and inhibiting an enzyme that may predict instances of cardiovascular disease
You may also be interested in...
diaDexus PLAC test for heart disease
Adjunctive, predictive laboratory test for congestive heart disease receives 510(k) clearance July 18. The blood test measures the level of the enzyme lipoprotein-associated phospholipase A2, which is created by macrophages when a person has CHD, FDA explains. "An elevated PLAC test result with an LDL-cholesterol level of less than 130 mg/dL gives doctors increased confidence that patients have two-to-three times the risk of having [CHD] when compared with patients having lower PLAC test results," according to the agency. The test was developed by San Francisco-based diaDexus and GlaxoSmithKline (1"The Gray Sheet" June 10, 2002, p. 8)...
diaDexus PLAC test for heart disease
Adjunctive, predictive laboratory test for congestive heart disease receives 510(k) clearance July 18. The blood test measures the level of the enzyme lipoprotein-associated phospholipase A2, which is created by macrophages when a person has CHD, FDA explains. "An elevated PLAC test result with an LDL-cholesterol level of less than 130 mg/dL gives doctors increased confidence that patients have two-to-three times the risk of having [CHD] when compared with patients having lower PLAC test results," according to the agency. The test was developed by San Francisco-based diaDexus and GlaxoSmithKline (1"The Gray Sheet" June 10, 2002, p. 8)...
Drug/Diagnostic Partnerships Fueled By Promise Of Reduced Trial Costs
Diagnostic manufacturers should be careful to keep their alliances with drug companies open enough to accommodate pharmacogenomic advances, panelists agreed at Thomas Weisel Partners' Healthcare Tailwinds 2002 meeting in Boston April 29